J&J Catheter Case: $442M Damages Tripled – Becker’s Hospital Review
A federal judge has dramatically increased the damages against Johnson & Johnson’s Biosense Webster to $442 million in a notable antitrust case. The ruling stems from the company’s illegal restriction of support services for reprocessed catheters, a determination that has sent ripples throughout the healthcare industry. This catheter antitrust judgment, coming from the U.S. District court for the Central district of california, reflects the severity of the company’s market practices, which directly impacted hospitals choosing to use reprocessed medical device reprocessing tools. news Directory 3 is closely following this groundbreaking case and the implications for Johnson & johnson. The original jury verdict of $147 million was tripled by the judge,underscoring the gravity of the violation. Biosense Webster is highly likely to appeal, setting the stage for further legal battles and raising questions about the future of support for providers using reprocessed medical devices.Discover what’s next as this case unfolds.
J&J Unit Faces $442M Fine in Catheter Antitrust Case
Updated June 10, 2025
Johnson & Johnson‘s Biosense Webster medical device unit has been hit with $442 million in damages, tripled by a federal judge in an antitrust case. The ruling,made in the U.S. District court for the Central District of California, follows a jury determination that the company illegally limited access to support services for hospitals using reprocessed electrophysiology catheters.
the original verdict, issued in May, found that Biosense Webster violated antitrust laws by withholding clinical support from facilities that opted for Innovative Health’s reprocessed catheters over new ones sold by the J&J subsidiary. This catheter antitrust case highlights the ongoing debate surrounding medical device reprocessing and Johnson & Johnson‘s market practices.
Judge James Selna affirmed the jury’s initial $147 million award and then increased it,citing federal and California antitrust statutes.
“This is a seismic result,” Daniel Vukelich, president and CEO of the Association of Medical Device Reprocessors, said. ”The court not only affirmed what the jury found — that Johnson & Johnson illegally monopolized and tied the market to undermine reprocessed medical devices — but took the additional step of tripling the damages, as allowed under antitrust law.”
What’s next
Biosense Webster may appeal the ruling. The case underscores the legal and ethical considerations surrounding the availability of support for reprocessed medical devices.